"The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced.
Adalimumab is the first and o"...
(nepafenac) Ophthalmic Suspension
ILEVRO (nepafenac ophthalmic suspension), 0.3% is a sterile, topical, nonsteroidal anti-inflammatory (NSAID) prodrug for ophthalmic use. EachmL of ILEVRO (nepafenac ophthalmic suspension), 0.3% contains 3 mg of nepafenac. Nepafenac is designated chemically as 2-amino-3- benzoylbenzeneacetamide with an empirical formula of C15H14N2O2.
The structural formula of nepafenac is:
Nepafenac is a yellow crystalline powder. The molecular weight of nepafenac is 254.28.
ILEVRO (nepafenac ophthalmic suspension), 0.3% is supplied as a sterile, aqueous suspension with a pH approximately of 6.8.
The osmolality of ILEVRO (nepafenac ophthalmic suspension), 0.3% is approximately 300 mOsm/kg.
Each mL of ILEVRO (nepafenac ophthalmic suspension), 0.3% contains: Active: nepafenac 0.3% Inactives: boric acid, propylene glycol, carbomer 974P, sodium chloride, guar gum, carboxymethylcellulose sodium, edentate disodium, benzalkonium chloride 0.005% (preservative), sodium hydroxide and/or hydrochloric acid to adjust pH and purified water, USP.
Last reviewed on RxList: 12/14/2015
This monograph has been modified to include the generic and brand name in many instances.
Additional Ilevro Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.